Studying the differences between pre-surgical and post-surgical Gleason scores is clearly “in fashion.” A third group has now reported that about 60 percent of their patients have a different Gleason score on biopsy than they do when the Gleason score is reassessed after surgery.
Filed under: Uncategorized | No Comments »
According to Beer et al., data from the recent ASCENT trial demonstrates that elevated C-reactive protein (CRP) levels in patients receiving docetaxel-based regimens for the treatment of hormone-refractory (also known as androgen-independent) prostate cancer is highly predictive of poor survival and a lower probability of PSA response to treatment. Perhaps a more patient-oriented way to look at this [...]
Filed under: Uncategorized | No Comments »
For our increasingly regular visitors, you might like to check out the some of the new content that has been added to the main site (as opposed to the blog) over the past couple of weeks:
Filed under: Diagnosis, Management, Treatment | No Comments »
Penson has recently reviewed available data on the methods use to assess the quality of care, the available quality measures in prostate cancer, and the existing literature on the quality of prostate cancer care in the USA.
Filed under: Management, Treatment | 1 Comment »
For many years, the facility at Loma Linda in California was the only commercially functional proton beam radiation facility in the USA. Now there are five such facilities (at Loma Linda, CA; Bloomington, IN; Boston, MA; Houston, TX; and Jacksonville, FL), with three more under construction and 10 more in the planning stage. About 8,000 [...]
Filed under: Management, Treatment | 6 Comments »
This appears to be another case of the need to prove the obvious.
According to a study recently completed at the University of Chicago and published in Urology, “Speeding up prostate-specific antigen (PSA) testing is preferred by patients but does not reduce their anxiety levels.”
Filed under: Management | 2 Comments »
The divisions within the medical community about the value of PSA in identifying patients with prostate cancer received a new airing today in the Chicago Sun-Times. While such articles are appropriate, they do not make it any easier for the average man to understand whether he should or shouldn’t be having regular tests to know [...]
Filed under: Diagnosis, Management | No Comments »
… we should all be proud of his OpEd in today’s issue of the Boston Globe. He understands that without commitment, there will be limited progress towards cures for all cancers, and not just prostate cancer.
Filed under: Uncategorized | No Comments »
Sometimes, apparently, we need to prove what would appear (at least at first sight) to be obvious.
D’Amico et al. have just published results demonstrating that continuing enlargement of the prostate in men receiving neoadjuvant hormone therapy prior to radiation therapy for treatment of T1c-T3cN0M0 disease is a significant indicator of future risk of PSA failure.
Filed under: Uncategorized | No Comments »
Mitchell and Chang have reviewed current controversies in the management of the substantial minority of patients (in developed countries at least) who are diagnosed with locally advanced or metastatic disease.
Filed under: Uncategorized | No Comments »
